Blarcamesine in Early Alzheimer Disease Phase 2b/3 Randomized Clinical Trial
Marwan N. Sabbagh, William R. Chezem, Kun Jin, Christopher U Missling, Anavex Life Sciences Research Group · 2025
Read Blarcamesine in Early Alzheimer Disease Phase 2b/3 Randomized Clinical Trial by Marwan N. Sabbagh, William R. Chezem, Kun Jin, Christopher U Missling, Anavex Life Sciences Research Group (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713060.txt.
Description
Marwan N Sabbagh and co-authors report a 2025 trial of blarcamesine, a daily capsule tested in early Alzheimer's disease. No approved oral treatment yet slows the disease itself. The drug switches on a cell receptor that helps restore balance inside cells, including the clearing of worn-out parts.
The trial enrolled 508 people with early disease at fifty-two centers in five countries and ran for forty-eight weeks. Scores for thinking and daily function declined less in the drug group than in the placebo group. The authors present the capsule as a possible oral option, while noting the need to weigh side effects and confirm the gains.
Catalog record
| CREATOR | Marwan N. Sabbagh, William R. Chezem, Kun Jin, Christopher U Missling, Anavex Life Sciences Research Group |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |